Solara reported its strongest quarter in 8 quarters with revenue of ₹392 crore and EBITDA of ₹61 crore, driven by a 12% QoQ revenue growth and 65% QoQ EBITDA growth.
The base business delivered 54% gross margins and 26% EBITDA margins, while the ibuprofen segment continued to be a drag with negative EBITDA.
The company reduced net debt by ₹158 crore (21%) in FY26 and has a line of sight to reduce it further to ~₹503 crore by end-May 2026 from rights issue proceeds.
Strategic options for the loss-making ibuprofen business are being evaluated by appointed bankers, with a conclusion expected in H1 FY27.